At the news
? BULLISHIMPACT 7/10 PRESS-RELEASE filed Jun 3, 2026 at 06:53 ET
Kura Oncology presented Phase 1a data at ASCO 2026 showing darlifarnib + adagrasib achieved confirmed objective response rates of 67% in pancreatic cancer, 50% in NSCLC, and 29% in KRAS inhibitor-naïve colorectal cancer, with tumor shrinkage in 77% of evaluable patients. The company announced a new platform study to accelerate darlifarnib combinations across targeted therapies, starting with darlifarnib + daraxonrasib in KRAS-mutant pancreatic cancer expected in early 2027. This is a significant clinical and strategic update for an early-stage biotech with a $796M market cap, but the data are preliminary and the platform study timeline is distant.
- Darlifarnib + adagrasib showed confirmed ORR of 67% in pancreatic cancer, 50% in NSCLC, and 29% in KRAS inhibitor-naïve CRC among 26 response-evaluable patients.
- Tumor shrinkage observed in 77% of patients overall and 94% of KRAS inhibitor-naïve patients.
- Clinical activity also seen in KRAS inhibitor-pretreated patients.
- Preclinical data show darlifarnib inhibits RHEB farnesylation and sustains mTORC1 suppression, addressing adaptive resistance to KRAS inhibition.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access